FBRX Forte Biosciences
- 0.537
- -0.011-2.01%
Forte Biosciences News
Rodman & Renshaw Initiates Forte Biosciences(FBRX.US) With Buy Rating, Announces Target Price $4
Rodman & Renshaw analyst Elemer Piros initiates coverage on $Forte Biosciences(FBRX.US)$ with a buy rating, and sets the target price at $4.According to TipRanks data, the analyst has a success rate o
Express News | Camac Fund LP - Forte Biosciences' Board Will Be Expanded to Nine Seats, One Incumbent Director Will Resign, Two Directors Selected by Camac Fund
Express News | Camac Fund LP Says on Pursuant to Settlement Agreement Forte Biosciences Will Form Committee of Board to Explore Strategic Alternatives
Express News | Camac Fund LP Says on June 11, Entered Into Settlement Agreement With Forte Biosciences - SEC Filing
Forte Biosciences Initiated at Buy by Brookline Capital
Forte Biosciences Initiated at Buy by Brookline Capital
Express News | Brookline Capital Initiates Coverage On Forte Biosciences With Buy Rating, Announces Price Target of $4
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. () (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as
Express News | CORRECTION: Forte Biosciences Q1 GAAP EPS $(0.16) Beats $(0.17) Estimate
Forte Biosciences | 10-Q: Quarterly report
Press Release: Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update DALLAS--(BUSINESS WIRE)--May 13, 2024-- Forte Biosciences, Inc. () (NASDAQ: FBRX), a clinical-stage biopharm
Express News | Forte Biosciences Q1 Operating Expenses USD 7.804 Million
Express News | Forte Biosciences Q1 Income From Operations USD -7.804 Million
Express News | Forte Biosciences Q1 Basic EPS USD -0.16
Forte Biosciences 1Q Loss $7.42M >FBRX
Forte Biosciences 1Q Loss $7.42M >FBRX
Forte Biosciences Raised to Buy From Neutral by Ladenburg Thalmann
Forte Biosciences Raised to Buy From Neutral by Ladenburg Thalmann
Ladenburg Thalmann Upgrades Forte Biosciences to Buy, Announces $2.75 Price Target
Ladenburg Thalmann analyst Michael Higgins upgrades Forte Biosciences (NASDAQ:FBRX) from Neutral to Buy and announces $2.75 price target.
Forte Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/08/2024 292.3% Ladenburg Thalmann → $2.75 Upgrades Neutral → Buy 09/20/2021 399.29% Chardan Capital $4
Buy Recommendation for Forte Biosciences on Strong Potential of Novel FB-102 Treatment and Market Position
Forte Biosciences GAAP EPS of -$1.00
Forte Biosciences, Inc. Announces 2023 EPS $(1.00) Vs $(0.80) YoY
2023 Operating ResultsResearch and development expenses were $21.9 million for the year ended December 31, 2023, compared to $5.6 million during the same period in 2022. The increase of $16.3 million
Analysis
Price Target
No Data
